Lacerta Therapeutics
Todd E. Golde is currently an advisor at Lacerta Therapeutics. Todd was previously the director of the University of Florida College of Medicine from December 2016 to August of 2022. Todd was also the director of 1Florida Alzheimer's Disease Research Center from December of 2009 to August of 2022. Todd has been a champion for neuroscience and neuromedicine research programs and has promoted and implemented a vision for these programs that is based on programmatic translational science.
Todd E. Golde has a BA in Biology Immunology from Amherst College, an MD PhD in Medicein, pathology from Case Western Reserve University School of Medicine, and is currently doing their residency in Pathology at the University of Pennsylvania School of Medicine.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Lacerta Therapeutics
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, LacertaTherapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.